Could This FDA Milestone Unlock Gilead’s (GILD) Next Big Growth Driver?

With a short percentage of shares outstanding of 2.07%, Gilead Sciences, Inc. (NASDAQ:GILD) is among the 7 Best Longevity and Anti-Aging Stocks to Buy.

On June 15, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the U.S. Food and Drug Administration accepted its supplemental New Drug Application for Yeztugo 300-mg tablets as a potential once-weekly oral pre-exposure prophylaxis (PrEP) treatment for HIV prevention. The Food and Drug Administration assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 2, 2027, marking an important regulatory milestone for the program. If approved, the therapy could expand Gilead’s HIV prevention portfolio by offering patients a convenient once-weekly oral dosing option.

On June 12, Gilead Sciences, Inc. (NASDAQ:GILD) announced the donation of more than 2,000 vials of its intravenous antiviral therapy remdesivir to the Republic of Uganda to support efforts to combat the ongoing Ebola Bundibugyo virus outbreak. The company stated that the donation reflects its commitment to responding rapidly to global health emergencies and leveraging its extensive experience in infectious disease management. Management emphasized that Gilead is working closely with partners and health authorities to help address the outbreak and support affected communities.

Founded in 1987 and headquartered in Foster City, California, Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics for life-threatening diseases, particularly in virology, oncology, and inflammation. It transforms fatal & chronic conditions (like HIV and Hepatitis C) into highly manageable, long-term states of health.

While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Most Overvalued Quantum Computing Stocks According to Short Sellers and 7 Best Pet Care Stocks to Buy for Consistent Recurring Revenue.

Disclosure: None.  Follow Insider Monkey on Google News.

1281292 - 11759070 - 1